Shire, Zymenex deal will be boon to HGT unit

Vertex aims at $320M in stock offering [February 19, 2009]

TKT investors to get $568M from Shire lawsuit [November 6, 2008]

Eisai closing MGI Pharma cancer lab [May 16, 2008]

Shire HGT to benefit from new office in Japan [February 20, 2009]

British drug firm Shire plc has acquired an experimental treatment for a rare disease from Danish biotech company Zymenex AS for $135 million.

The treatment, an enzyme-replacement therapy for patients with metachromatic leukodystrophy, is expected to become part of Shire's HGT business, which is based in Cambridge, Mass.

The treatment is now in Phase 1-2 clinical trials and expands the HGT unit's pipeline of drugs for rare diseases, according to Shire (NASDAQ: SHPGY) officials.

Metachromatic leukodystrophy is a disease caused by a deficiency in an enzyme that allows storage of sulphatides in nerve cells and other organs, leading to progressive neurological damage, according to Shire. The disease affects some 2,000 people in the developed world.

Shire HGT, which is in the midst of moving its headquarters from Cambridge to larger facilities Lexington, is focused on marketing and developing biological treatments for serious diseases. The business unit employs 675 workers in Massachusetts and a total 750 employees worldwide.

Its parent company's shares also trade on the London Stock Exchange under the ticker "SHP."

Comments

If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.